4 November 2013Biotechnology

New frontiers: potential barriers to patenting induced totipotent stem cell technology

It has for some years been possible to create pluripotent stem cells (stem cells capable of differentiating into many, but not all, other cell types of the body) from fully differentiated adult cells (so called ‘induced pluripotent stem cells’ [iPS cells]).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Life sciences leaders recognised at LSPN Awards USA 2025

Taylor Wessing expands in Europe with Paris team

ResMed voids sleep apnoea tech patent at PTAB

Novartis settles with licensee of blood cancer therapy day before trial

Biotech and healthcare expert returns to Latham & Watkins

Commercialising genomic tech in Nigeria

Medical company sees $452m trade secrets award cut by 87%

Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO

New frontiers: potential barriers to patenting induced totipotent stem cell technology

Editor's picks

Editor's picks

More features